Clinical and microbiological features and outcomes of mucormycosis in critically ill patients.
暂无分享,去创建一个
D. Busch | R. Schmid | M. Verbeek | S. Rasch | T. Lahmer | R. Okrojek | K. Rothe | M. Heim | Krischan Braitsch
[1] A. Skiada,et al. Epidemiology and Diagnosis of Mucormycosis: An Update , 2020, Journal of fungi.
[2] C. Schwebel,et al. Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy , 2020, Annals of Intensive Care.
[3] H. Badali,et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. , 2019, The Lancet. Infectious diseases.
[4] M. Kinzig,et al. Influence of Sustained Low-Efficiency Dialysis Treatment on Isavuconazole Plasma Levels in Critically Ill Patients , 2019, Antimicrobial Agents and Chemotherapy.
[5] A. Trampuz,et al. A case report of cutaneous mucormycosis of the hand after minor trauma in a patient with acute myeloid leukaemia , 2019, Trauma case reports.
[6] R. Wolfe,et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[7] D. Kontoyiannis,et al. Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] T. Walsh,et al. Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials , 2018, Antimicrobial Agents and Chemotherapy.
[9] C. Beigelman-Aubry,et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[10] M. Hoenigl,et al. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy , 2018, Drug design, development and therapy.
[11] A. Ibrahim,et al. Challenges in the diagnosis and treatment of mucormycosis. , 2018, Medical mycology.
[12] M. Bassetti,et al. Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review , 2017, Infectious Diseases and Therapy.
[13] P. Escribano,et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates , 2017, PloS one.
[14] A. Limper,et al. Pulmonary mucormycosis: clinical features and outcomes , 2017, Infection.
[15] L. Scott,et al. Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis , 2016, Drugs.
[16] D. Kontoyiannis,et al. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[17] J. Perfect,et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. , 2016, The Lancet. Infectious diseases.
[18] D. Galarza-Delgado,et al. Clinical Features and Outcome of Mucormycosis , 2014, Interdisciplinary perspectives on infectious diseases.
[19] G. Petrikkos,et al. Epidemiology of mucormycosis in Europe. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[20] C. Lass‐Flörl,et al. Mucormycosis--from the pathogens to the disease. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[21] L. Pagano,et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[22] M. Younes,et al. A rare cause of gastrointestinal bleeding in the intensive care unit. Healthcare-associated mucormycosis. , 2014, Gastroenterology.
[23] L. Pagano,et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries , 2013, Haematologica.
[24] D. Kontoyiannis,et al. Invasive fungal infections in patients with cancer in the Intensive Care Unit. , 2012, International journal of antimicrobial agents.
[25] C. Elie,et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] D. Milner,et al. Molecular Methods To Improve Diagnosis and Identification of Mucormycosis , 2011, Journal of Clinical Microbiology.
[27] R. Goldberg,et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] K. Eva,et al. Reassessing the methods of medical record review studies in emergency medicine research. , 2005, Annals of emergency medicine.
[30] J. Steiner,et al. Chart reviews in emergency medicine research: Where are the methods? , 1996, Annals of emergency medicine.